Tgfb3 Knockout cell line(B16-F10)
Catalog Number: KO01210
Price: Online Inquiry
Catalog Number: KO01210
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Tgfb3 Knockout cell line(B16-F10) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epithelioid, adherent cell |
Passage ratio | 1:3~1:4 |
species | Mouse |
Gene | Tgfb3 |
Gene ID | 21809 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90%RPMI-1640+10%FBS |
Parental Cell Line | B16-F10 |
Quality Control | Genotype: Tgfb3 Knockout cell line(B16-F10) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | transforming growth factor, beta 3provided by MGI |
Also known as | Tgfb-3; TGF-beta-3 |
Gene Description | This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is found in either a latent form composed of a mature peptide homodimer, a LAP homodimer, and a latent TGF-beta binding protein, or in an active form consisting solely of the mature peptide homodimer. The mature peptide may also form heterodimers with other TGF-beta family members. This protein is involved in embryogenesis and cell differentiation, and may play a role in wound healing. Homozygous knockout mice for this gene exhibit cleft palate, delayed pulmonary development and neonatal death. [provided by RefSeq, Aug 2016] |
Expression | Broad expression in limb E14.5 (RPKM 30.0), ovary adult (RPKM 18.2) and 20 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.